Participants who developed CRS displayed an elevated induction of CXCL10, IFN-γ, IL-6, and TNF-α upon their first 0.4 mg dose (Figure 2), which supports dose-dependent cytokine induction. This evidence concerns the gene CXCL10 and congenital rubella syndrome.